Faculty Collaboration Database

1. Schwartz CL, Bender KS, Burke PJ, Kan JS, Civin CI. QT interval prolongation and cardiac dysrhythmia in a patient receiving amsacrine. Cancer Treat Rep. 1984;68(7-8):1043-4.

2. Noga SJ, Donnenberg AD, Schwartz CL, Strauss LC, Civin CI, Santos GW. Development of a simplified counterflow centrifugation elutriation procedure for depletion of lymphocytes from human bone marrow. Transplantation. 1986 Feb;41(2):220-9.

3. Noga SJ, Cremo CA, Duff SC, Schwartz CL, Melaragno A, Civin CI, Donnenberg AD. Large scale separation of human bone marrow by counterflow centrifugation elutriation. J Immunol Methods. 1986 Sep 27;92(2):211-8.

4. Noga SJ, Schwartz CL, Civin CI, Loken M, Donnenberg AD. Rapid separation of whole human bone marrow aspirates by counterflow centrifugation elutriation. Transplantation. 1987 Mar;43(3):438-40.

5. Schwartz CL, Minniti CP, Harwood P, Na S, Banquerigo ML, Strauss LC, Kurtzberg J, Smith SD, Civin CI. Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin. J Clin Oncol. 1987 Dec;5(12):1900-11.

6. Henrickson KJ, Powell KR, Schwartz CL. A dilute solution of vancomycin and heparin retains antibacterial and anticoagulant activities. J Infect Dis. 1988 Mar;157(3):600-1.

7. Schwartz CL, Miller NR, Wharam MD, Leventhal BG. The optic nerve as the site of initial relapse in childhood acute lymphoblastic leukemia. Cancer. 1989 Apr 15;63(8):1616-20.

8. Schwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol. 1990 Sep;8(9):1591-7.

9. Schwartz CL. Creating life on the plateau: reproductive potential in survivors of childhood Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):1099-100.

10. Wang N, Cedrone E, Dry J, Skuse GR, Schwartz C, Terryberry S. Transposition of the oncogene ets-1 in t(11;19) translocation in acute leukemia. Cancer Genet Cytogenet. 1990 Dec;50(2):199-205.

11. Tulikangas P, Hobbie W, Schwartz CL. Cyclophosphamide treatment for childhood leukemia: Effects on reproductive function. J Univ Rochester Med Center, 1991.

12. Schwartz CL, Hobbie WL, Truesdell S, Constine LC, Clark EB. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol. 1993 Oct;11(10):1906-10.

13. Rosier RN, Teot LA, Hicks DG, Schwartz C, O'Keefe RJ, Puzas JE. Multiple drug resistance in osteosarcoma. Iowa Orthop J. 1995;15:66-73. PMCID: PMC2329065

14. Korones DN, Weidner S, Schwartz CL. Intermittent high-dose deferoxamine for patients with iron overload and sickle anemia. Int J Pediatr Hematol/Oncol(3):53-6, 1996.

15. O'Reilly R, Link M, Fletcher B, Gebhardt M, Krance R, Meyers P, Neff J, Schwartz C. NCCN pediatric osteosarcoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec;10(12):1799-806, 1812.

16. Dome JS, Schwartz CL. Osteosarcoma. Cancer Treat Res. 1997;92:215-51.

17. Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.

18. Walsh TJ, Finberg R, Arndt C, Hiemenz J, Schwartz CL, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. A Randomized, Double-Blind, Multicenter Trial of Liposomal Amphotericin B versus Conventional Amphotericin B for Empirical Antifungal Therapy of Persistently Febrile Neutropenic Patients. N Engl J Med(11):794-771, 1999.

19. Spunt SL, Lobe TE, Pappo AS, Parham DM, Wharam MD, Arndt C, Anderson JR, Crist WM, Paidas C, Wiener E, Andrassy RJ, Schwartz CL. Rhabdomyosarcoma of the Biliary Tract in Children and Adolescents - The Intergroup Rhabdomyosarcoma Study Group Experience (1972-98). J. Pediatr Surg(35):309-321, 2000.

20. Spunt SL, Lobe TE, Pappo AS, Parham DM, Wharam MD Jr, Arndt C, Anderson JR, Crist WM, Paidas C, Wiener E, Andrassy RJ, Schwartz CL. Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma. J Pediatr Surg. 2000 Feb;35(2):309-16.

21. Lipton JM, Federman N, Khabbaze Y, Schwartz CL, Hilliard LM, Clark JI, Vlachos A, Diamond-Black Anemia Registry. Osteogenic sarcoma associated with Diamond-Blackfan anemia: a report from the Diamond-Blackfan Anemia Registry. J Pediatr Hematol Oncol. 2001 Jan;23(1):39-44.

22. Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, Sallan SE. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001 Feb 15;19(4):1040-6.

23. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, Gebhardt MC, Schwartz CL, Link M, Grier HE. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002 Jan 15;20(2):426-33.

24. Meij P, Vervoort MB, Bloemena E, Schouten TE, Schwartz C, Grufferman S, Ambinder RF, Middeldorp JM. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. J Med Virol. 2002 Nov;68(3):370-7.

25. Welsh JS, Thurman SA, Borzillary S, Schwartz CL, Howard SP. Sm-153 EDTMP for recurrent metastatic osteosarcoma. Clin Adv Hematol Oncol. 2003 Mar;1(3):181-3; discussion 183.

26. Adams MJ, Lipshultz SE, Schwartz C, Fajardo LF, Coen V, Constine LS. Radiation-associated cardiovascular disease: manifestations and management. Semin Radiat Oncol. 2003 Jul;13(3):346-56.

27. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003 Nov 15;9(15):5442-53.

28. Schwartz CL. Health status of adult long-term survivors of childhood cancer:a report from the Childhood Cancer Survivor Study. J Pediatr. 2004 Mar;144(3):407-8.

29. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005 Mar 20;23(9):2004-11.

30. Schwartz CL. Special issues in pediatric Hodgkin's disease. Eur J Haematol Suppl. 2005 Jul(66):55-62.

31. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DN, Walsh TJ. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005 Aug;49(8):3317-24. PMCID: PMC1196271

32. Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005 Nov;49(11):4536-45. PMCID: PMC1280172

33. Wimmer RS, Chauvenet AR, London WB, Villaluna D, de Alarcon PA, Schwartz CL. APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. Pediatr Blood Cancer. 2006 Mar;46(3):320-4.

34. Kung FH, Schwartz CL, Ferree CR, London WB, Ternberg JL, Behm FG, Wharam MD, Falletta JM, de Alarcon P, Chauvenet AR, Children's Oncology Group. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2006 Jun;28(6):362-8.

35. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL, Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006 Oct 12;355(15):1572-82.

36. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007 Feb 10;25(5):493-500.

37. Ehrlich PF, Friedman DL, Schwartz CL, Children Oncology Group Hodgkin Lymphoma study section. Monitoring diagnostic accuracy and complications. A report from the Children's Oncology Group Hodgkin lymphoma study. J Pediatr Surg. 2007 May;42(5):788-91.

38. Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P, Children's Oncology Group. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol. 2007 May 20;25(15):2057-62.

39. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ, ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007 Sep 01;25(25):3991-4008.

40. Mahone EM, Prahme MC, Ruble K, Mostofsky SH, Schwartz CL. Motor and perceptual timing deficits among survivors of childhood leukemia. J Pediatr Psychol. 2007 Sep;32(8):918-25.

41. Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007 Oct;51(10):3714-9. PMCID: PMC2043253

42. Terlou A, Ruble K, Stapert AF, Chang HC, Rowe PC, Schwartz CL. Orthostatic intolerance in survivors of childhood cancer. Eur J Cancer. 2007 Dec;43(18):2685-90.

43. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE, Children's Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008 Feb 01;26(4):633-8.

44. Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer. 2008 Mar;50(3):667-70.

45. Lucas KG, Schwartz C, Kaplan J. Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma. Pediatr Blood Cancer. 2008 Jul;51(1):142-4.

46. Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, Basu SK, Kun LE, Ng A, Mauch P, Sandhu A, Culakova E, Lyman G, Mendenhall N. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008 Sep 01;72(1):24-33. PMCID: PMC3531236

47. Basu SK, Schwartz C, Fisher SG, Hudson MM, Tarbell N, Muhs A, Marcus KJ, Mendenhall N, Mauch P, Kun LE, Constine LS. Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2008 Sep 01;72(1):34-40. PMCID: PMC3532026

48. Trask CL, Welch JJ, Manley P, Jelalian E, Schwartz CL. Parental needs for information related to neurocognitive late effects from pediatric cancer and its treatment. Pediatr Blood Cancer. 2009 Feb;52(2):273-9.

49. Cole PD, Schwartz CL, Drachtman RA, de Alarcon PA, Chen L, Trippett TM. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol. 2009 Mar 20;27(9):1456-61. PMCID: PMC2668553

50. Loeb DM, Garrett-Mayer E, Hobbs RF, Prideaux AR, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL. Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer. 2009 Jun 01;115(11):2514-22. PMCID: PMC2974628

51. Schwartz CL, Constine LS, Villaluna D, London WB, Hutchison RE, Sposto R, Lipshultz SE, Turner CS, deAlarcon PA, Chauvenet A. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009 Sep 03;114(10):2051-9. PMCID: PMC2744567

52. Kelly MJ, Vivier PM, Panken TM, Schwartz CL. Bacteremia in febrile nonneutropenic pediatric oncology patients. Pediatr Blood Cancer. 2010 Jan;54(1):83-7.

53. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18;115(7):1351-3. PMCID: PMC2826760

54. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O'Holleran EW, Neuberg DS, Cohen HJ, Sallan SE. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010 Feb;24(2):320-34. PMCID: PMC2820141

55. Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Curr Probl Cancer. 2010;34(3):211-27.

56. Fitzgerald TJ, Bishop-Jodoin M, Cicchetti MG, Hanusik R, Kessel S, Laurie F, McCarten KM, Moni J, Pieters RS, Rosen N, Ulin K, Urie M, Chauvenet AR, Constine LS, Deye J, Vikram B, Friedman D, Marcus RB Jr, Mendenhall NP, Williams JL, Purdy J, Saltz J, Schwartz CL, White KS, Wolden S. Quality of radiotherapy reporting in randomized controlled trials of Hodgkin's lymphoma and non-Hodgkin's lymphoma: in regard to Bekelman and Yahalom (Int J Radiat Oncol Biol Phys 2009;73:492-498). Int J Radiat Oncol Biol Phys. 2010 May 01;77(1):315-6. PMCID: PMC2908913

57. Cole PD, McCarten KM, Drachtman RA, Alarcon Pd, Chen L, Trippett TM, Schwartz CL. Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report. Pediatr Hematol Oncol. 2010 Nov;27(8):650-7. PMCID: PMC3083978

58. Loeb DM, Hobbs RF, Okoli A, Chen AR, Cho S, Srinivasan S, Sgouros G, Shokek O, Wharam MD Jr, Scott T, Schwartz CL. Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma. Cancer. 2010 Dec 01;116(23):5470-8. PMCID: PMC2991401

59. Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II. J Am Coll Radiol. 2011 May;8(5):302-8.

60. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdière C, Michon B, Schorin M, Schwartz CL, Cohen HJ, Lipshultz SE, Silverman LB, Sallan SE. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011 Jun;47(9):1373-9. PMCID: PMC3736806

61. Kenney LB, Bradeen H, Kadan-Lottick NS, Diller L, Homans A, Schwartz CL. The current status of follow-up services for childhood cancer survivors, are we meeting goals and expectations: a report from the Consortium for New England Childhood Cancer Survivors. Pediatr Blood Cancer. 2011 Dec 01;57(6):1062-6.

62. Voss SD, Chen L, Constine LS, Chauvenet A, Fitzgerald TJ, Kaste SC, Slovis T, Schwartz CL. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20;30(21):2635-40. PMCID: PMC4559601

63. Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer. 2012 Sep 15;118(18):4597-605. PMCID: PMC4008337

64. Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. PMCID: PMC3468662

65. Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR, Hoppe BS, Ng A, Roberts KB, Shapiro R, Wilder RB, Yunes MJ, Constine LS. ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma. Pediatr Blood Cancer. 2014 Jul;61(7):1305-12.

66. Friedman DL, Chen L, Wolden S, Buxton A, McCarten K, FitzGerald TJ, Kessel S, De Alarcon PA, Chen AR, Kobrinsky N, Ehrlich P, Hutchison RE, Constine LS, Schwartz CL. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014 Nov 10;32(32):3651-8. PMCID: PMC4220044

67. Gorlick S, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gill J, Geller D, Randall RL, Janeway K, Schwartz C, Grier H, Meyers PA, Gorlick R, Bernstein M, Marina N. HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatr Blood Cancer. 2014 Sep;61(9):1558-64. PMCID: PMC4288578

68. Trippett TM, Schwartz CL, Guillerman RP, Gamis AS, Gardner S, Hogan S, London WB, Chen L, de Alarcon P. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Pediatr Blood Cancer. 2015 Jan;62(1):60-4. PMCID: PMC4465390

69. Harrison DJ, Schwartz C. Survivorship. J Surg Oncol. 2015 Apr;111(5):648-55.

70. Dharmarajan KV, Friedman DL, FitzGerald TJ, McCarten KM, Constine LS, Chen L, Kessel SK, Iandoli M, Laurie F, Schwartz CL, Wolden SL. Radiotherapy quality assurance report from children's oncology group AHOD0031. Int J Radiat Oncol Biol Phys. 2015 Apr 01;91(5):1065-71. PMCID: PMC5240783

71. Dharmarajan KV, Friedman DL, Schwartz CL, Chen L, FitzGerald TJ, McCarten KM, Kessel SK, Iandoli M, Constine LS, Wolden SL. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2015 May 01;92(1):60-6. PMCID: PMC4395527

72. Horton TM, Drachtman RA, Chen L, Cole PD, McCarten K, Voss S, Guillerman RP, Buxton A, Howard SC, Hogan SM, Sheehan AM, López-Terrada D, Mrazek MD, Agrawal N, Wu MF, Liu H, De Alarcon PA, Trippet TM, Schwartz CL. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. Br J Haematol. 2015 Jul;170(1):118-22. PMCID: PMC4478135

73. Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Constine LS, Freyer DR, Lipshultz SE, Armenian SH. Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. J Clin Oncol. 2015 Aug 20;33(24):2639-45. PMCID: PMC4534526

74. Macpherson CF, Hooke MC, Friedman DL, Campbell K, Withycombe J, Schwartz CL, Kelly K, Meza J. Exercise and Fatigue in Adolescent and Young Adult Survivors of Hodgkin Lymphoma: A Report from the Children's Oncology Group. J Adolesc Young Adult Oncol. 2015 Sep;4(3):137-40. PMCID: PMC4575513

75. Keller FG, Castellino SM, Chen L, Pei Q, Voss SD, McCarten KM, Senn SL, Buxton A, Constine LS, Schwartz CL. Results of the AHOD0431 Trial of Response Adapted Therapy and a Salvage Strategy for Limited-Stage Classical Hodgkin Lymphoma: A Report from the Children’s Oncology Group, J Clin Oncol, Resubmitted, 2016.

76. Schwartz CL, Wexler LH, Krailo MD, Teot LA, Devidas M, Steinherz LJ, Goorin AM, Gebhardt MC, Healey JH, Sato JK, Meyers PA, Grier HE, Bernstein ML, Lipshultz SE. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2016 Jan;63(1):54-61. PMCID: PMC4779061

77. Appel BE, Chen L, Buxton AB, Hutchison RE, Hodgson DC, Ehrlich PF, Constine LS, Schwartz CL. Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group. J Clin Oncol. 2016 Jul 10;34(20):2372-9. PMCID: PMC4981978

78. Bishop MW, Chang YC, Krailo MD, Meyers PA, Provisor AJ, Schwartz CL, Marina NM, Teot LA, Gebhardt MC, Gorlick R, Janeway KA, Chou AJ. Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2016 Oct;63(10):1737-43. PMCID: PMC5136499

79. Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct;17(10):1396-1408. PMCID: PMC5052459

80. Charpentier AM, Friedman DL, Wolden S, Schwartz C, Gill B, Sykes J, Albert-Green A, Kelly KM, Constine LS, Hodgson DC. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial. Int J Radiat Oncol Biol Phys. 2016 Dec 01;96(5):943-950. PMCID: PMC5584603

81. Welch JGJ, Schwartz CL, Higman M, Chen L, Buxton A, Kanakry JA, Kahwash SB, Hutchison RE, Friedman DL, Ambinder RF. Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. Blood Advances, In Press, 2017.

82. Kaul S, Avila JC, Mutambudzi M, Russell H, Kirchhoff AC, Schwartz CL. Mental distress and health care use among survivors of adolescent and young adult cancer: A cross-sectional analysis of the National Health Interview Survey. Cancer. 2017 Mar 01;123(5):869-878.

83. Schwartz CL, Chen L, McCarten K, Wolden S, Constine LS, Hutchison RE, de Alarcon PA, Keller FG, Kelly KM, Trippet TA, Voss SD, Friedman DL. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 Apr;64(4). PMCID: PMC5702912

84. Esbenshade AJ, Zhao Z, Aftandilian C, Saab R, Wattier RL, Beauchemin M, Miller TP, Wilkes JJ, Kelly MJ, Fernbach A, Jeng M, Schwartz CL, Dvorak CC, Shyr Y, Moons KGM, Sulis ML, Friedman DL. Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. Cancer. 2017 Oct 01;123(19):3781-3790. PMCID: PMC5610619

85. Fernández KS, Schwartz CL, Chen L, Constine LS, Chauvenet A, de Alarcón PA. Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report. Pediatr Blood Cancer. 2017 Dec;64(12). PMCID: PMC5799083

86. Esbenshade AJ, Zhao Z, Aftandilian C, Saab R, Wattier RL, Beauchemin M, Miller TP, Wilkes JJ, Kelly MJ, Fernbach A, Jeng M, Schwartz CL, Dvorak CC, Shyr Y, Moons KGM, Sulis ML, Friedman DL. Multisite external validation of a risk prediction model for the diagnosis of blood stream infections in febrile pediatric oncology patients without severe neutropenia. Cancer. 2017 Oct 01;123(19):3781-3790. PMCID: PMC5610619

87. Fernández KS, Schwartz CL, Chen L, Constine LS, Chauvenet A, de Alarcón PA. Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report. Pediatr Blood Cancer. 2017 Dec;64(12). PMCID: PMC5799083

88. Aldrink JH, Appel B, Kaplan JA, Hutchison RE, Schwartz CL, Kelly KM, McCarten K, Ehrlich PF. Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma. J Pediatr Hematol Oncol. 2018 Apr;40(3):246-247. PMCID: PMC5866194

89. Welch JJG, Schwartz CL, Higman M, Chen L, Buxton A, Kanakry JA, Kahwash SB, Hutchison RE, Friedman DL, Ambinder RF. Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. Blood Adv. 2017 Apr 25;1(11):681-684. PMCID: PMC5727814

90. Keller FG, Castellino SM, Chen L, Pei Q, Voss SD, McCarten KM, Senn SL, Buxton AB, Bush R, Constine LS, Schwartz CL. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group. Cancer. 2018 Aug 01;124(15):3210-3219. PMCID: PMC6097921

91. Parzuchowski A, Bush R, Pei Q, Friedman DL, FitzGerald TJ, Wolden SL, Dharmarajan KV, Constine LS, Laurie F, Kessel SK, Appel B, Fernandez K, Punnett A, Schwartz CL, Cox J, Terezakis SA. Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031. Int J Radiat Oncol Biol Phys. 2018 Apr 01;100(5):1119-1125. PMCID: PMC6555555

92. McCarten KM, Metzger ML, Drachtman RA, Pei Q, Friedman DL, Schwartz CL, Kelly KM. Significance of pleural effusion at diagnosis in pediatric Hodgkin lymphoma: a report from Children's Oncology Group protocol AHOD0031. Pediatr Radiol. 2018 Nov;48(12):1736-1744. PMCID: PMC6208959

93. Marks LJ, McCarten KM, Pei Q, Friedman DL, Schwartz CL, Kelly KM. Pericardial effusion in Hodgkin lymphoma: a report from the Children's Oncology Group AHOD0031 protocol. Blood. 2018 Sep 13;132(11):1208-1211. PMCID: PMC6137557

94. Welch JJG, Kenney LB, Hirway P, Usmani GN, Kadan-Lottick N, Grewal SS, Huang M, Bradeen H, Ader J, Diller L, Schwartz CL. Understanding predictors of continued long-term pediatric cancer care across the region: A report from the Consortium for New England Childhood Cancer Survivors. Pediatr Blood Cancer. 2017 Oct;64(10).

95. Harrison DJ, Schwartz CL. Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease. Curr Treat Options Oncol. 2017 Apr;18(4):24.

96. Mauz-Körholz C, Metzger ML, Kelly KM, Schwartz CL, Castellanos ME, Dieckmann K, Kluge R, Körholz D. Pediatric Hodgkin Lymphoma. J Clin Oncol. 2015 Sep 20;33(27):2975-85.

97. Borinstein SC, Barkauskas DA, Bernstein M, Goorin A, Gorlick R, Krailo M, Schwartz CL, Wexler LH, Toretsky JA. Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. Pediatr Blood Cancer. 2014 Apr;61(4):749-52. PMCID: PMC3946315

98. Schwartz CL. Prognostic factors in pediatric Hodgkin disease. Curr Oncol Rep. 2003 Nov;5(6):498-504.

99. Schwartz CL. The management of Hodgkin disease in the young child. Curr Opin Pediatr. 2003 Feb;15(1):10-6.

100. Schwartz CL. Long-term survivors of childhood cancer: the late effects of therapy. Oncologist. 1999;4(1):45-54.

101. Schwartz CL. Late effects of treatment in long-term survivors of cancer. Cancer Treat Rev. 1995 Jul;21(4):355-66.

102. Hobbie WL, Schwartz CL. Endocrine late effects among survivors of cancer. Semin Oncol Nurs. 1989 Feb;5(1):14-21.

103. Schwartz CL, Cohen HJ. Preleukemic syndromes and other syndromes predisposing to leukemia. Pediatr Clin North Am. 1988 Aug;35(4):853-71.

104. Schwartz CL, Henrickson KJ, Roghmann K, Powell K.. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheter with vancomycin susceptible organisms. J Clin Oncol. (8):1591-1597.

105. Untanu RV, Back J, Appel B, Pei Q, Chen L, Buxton A, Hodgson DC, Ehrlich PF, Constine LS, Schwartz CL, Hutchison RE. Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 Jan;65(1). PMCID: PMC5699946

106. Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM. Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer. 2018 Jan 01;124(1):136-144. PMCID: PMC5735034

107. Schwartz CL. Creating life on the plateau: Reproductive potential in survivors of childhood Hodgkin's disease Int J Rad Onc Biol Phys. (19):1099-1100.

108. Spraker-Perlman HL, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Doski J, Gorlick R, Janeway KA, Isakoff MS. Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2019 Jan;66(1):e27444. PMCID: PMC6249072

109. Marks LJ, Pei Q, Bush R, Buxton A, Appel B, Kelly KM, Schwartz CL, Friedman DL. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 Dec;65(12):e27375. PMCID: PMC6192844

110. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019 Mar;109:36-50. PMCID: PMC6506906

111. Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY,Schwartz C. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Br J Haematol. 2019 Jun, [Epub ahead of print]

112. Lisa Kopp; Richard B. Womer, MD; Cindy L. Schwartz, MD, MPH; David H. Ebb, MD; Vivian I. Franco, MS; David Hall, MS; Donald A. Barkauskas, PhD; Mark D. Krailo, PhD; Holcombe E. Grier, MD; Paul A. Meyers, MD; Leonard H. Wexler, MD; Neyssa M. Marina, MD, MS; Katherine A. Janeway, MD; Richard Gorlick, MD; Mark L. Bernstein, MD; Steven E. Lipshultz, MD. Effects of Dexrazoxane on Doxorubicin-Related Cardiotoxicity and Second Malignant Neoplasms in Children with Osteosarcoma: A Report from the Children’s Oncology Group* Cardio-Oncology, In Press 2019

113. Kahn JM, Kelly KM, Pei Q, Bush R, Friedman DL, Keller FG, Bhatia S, Henderson TO, Schwartz CL, Castellino SM. Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children's Oncology Group Study. J Clin Oncol. 2019 Nov 10;37(32):3009-3017. PMCID: PMC6839907

114. Schwartz CL. Creating a bridge for transition: From pediatric cancer survival to life-long, risk-based health care of the adult cancer survivor. Cancer. 2020 Feb 01;126(3):473-476.

115. Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Br J Haematol. 2019 Oct;187(1):39-48. PMCID: PMC6857800

116. Hall GW, Schwartz CL, Daw S, Constine LS. Pediatric hodgkin lymphoma Hematologic Malignancies. 1 December 2015;6:253-270.

117. Schwartz CL, Hobbie WL, Constine LS. Algorithms of late effects by disease Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach: Third Edition. 3 September 2015:1-13.

118. Schwartz CL, Hobbie WL, Constine LS. Facilitating assessment of late effects by organ system Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach: Third Edition. 3 September 2015:15-32.

119. Dhakal S, Weiner D, Schwartz C, Constine LS. Pulmonary effects of antineoplastic therapy Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach: Third Edition. 3 September 2015:201-227.

120. Milano MT, Dhakal S, Schwartz CL, Constine LS. The thyroid gland Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach: Third Edition. 3 September 2015:151-166.

121. Schwartz CL, Hobbie WL, Constine LS, Ruccione KS. Survivors of childhood and adolescent cancer: A multidisciplinary approach: Third Edition Survivors of Childhood and Adolescent Cancer: A Multidisciplinary Approach: Third Edition. 3 September 2015:1-436.

122. Schwartz CL, Hobbie WL, Constine LS. Facilitating assessment of late effects by organ system Pediatric Oncology. 2015;2015:15-32.

123. Hall GW, Schwartz CL, Daw S, Constine LS. Pediatric hodgkin lymphoma Hodgkin Lymphoma: A Comprehensive Overview, Second Edition. 1 January 2015:253-270.

124. Hall GW, Schwartz C, Daw S, Constine LS. Pediatric hodgkin lymphoma Hematologic Malignancies. 2020:277-296.

125. Kopp LM, Womer RB, Schwartz CL, Ebb DH, Franco VI, Hall D, Barkauskas DA, Krailo MD, Grier HE, Meyers PA, Wexler LH, Marina NM, Janeway KA, Gorlick R, Bernstein ML, Lipshultz SE, Children’s Oncology Group. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group. Cardiooncology. 2019;5:15. PMCID: PMC7048050

126. Schwartz CL, Hobbie WL, Constine LS. Algorithms of late effects by disease Pediatric Oncology. 2015;2015:1-13.

127. Friedman DL, Schwartz CL. Hodgkin lymphoma in children The Lymphoid Neoplasms 3ed. 1 January 2010:1279-1298.

128. Carver J, Shapiro C, Ng A, Jacobs L, Schwartz C, et al. American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects. J Clin Oncol 25(25):3991-4008, 2007.

129. Borinstein SC, Barkauskas DA, Bernstein M, Goorin A, Gorlick R, Krailo M, Schwartz CL, Wexler LH, Toretsky JA. Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study. Pediatr Blood Cancer. 2014 Apr;61(4):749-52. doi: 10.1002/pbc.24778. Epub 2013 Oct 31. PubMed PMID: 24178953; PubMed Central PMCID: PMC3946315.

130. Welch JJG, Kenney LB, Hirway P, Usmani GN, Kadan-Lottick N, Grewal SS, Huang M, Bradeen H, Ader J, Diller L, Schwartz CL. Understanding predictors of continued long-term pediatric cancer care across the region: A report from the Consortium for New England Childhood Cancer Survivors. Pediatr Blood Cancer. 2017 Apr 28. doi: 10.1002/pbc.26564. [Epub ahead of print] PubMed PMID: 28453181.

131. Weisman AJ, Kim J, Lee I, McCarten KM, Kessel S, Schwartz CL, Kelly KM, Jeraj R, Cho Sy, Bradshaw TJ. Automated quantification of baseline imaging PET metrics FDG PET/CT images of pediatric Hodgkin lymphjmapatietns. EJNMMI Physics, submitted, 2020.

132. Dhakal S, Weiner D, Schwartz C, Constine LS. Pulmonary effects of antineoplastic therapy Pediatric Oncology. 2015;2015:201-227.

133. Milano MT, Dhakal S, Schwartz CL, Constine LS. The thyroid gland Pediatric Oncology. 2015;2015:151-166.

134. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Ferguson WS, Gebhardt MC, Goorin AM, Kleinerman ES, Nieder ML, Wells RJ, Sato JK, Grier HE. In reply Journal of Clinical Oncology. 2008;26(18):3104-3105.

135. Carver JR, Jacobs LA, Vaughn DJ, Shapiro CL, Ng A, Virgo KS, Hagerty K, Somerfield MR, Schwartz CL. In reply [4] Journal of Clinical Oncology. 1 January 2008;26(1):162.

136. Schwartz CL, Gorlick R, Teot L, Krailo M, Goorin A, Grier HE, Bernstein ML, Meyers P. In reply [10] Journal of Clinical Oncology. 20 October 2007;25(30):4860-4861.

137. Schwartz CL, Constine LS, London WB, Sposto R, Friedman DL, Tebbi CK, Mendenhall N, Chen AR, De Alarcon PA, Villaluna D, Chauvenet AR. In reply [2] Journal of Clinical Oncology. 10 October 2007;25(29):4690-4691.

138. Schwartz CL, Constine LS, London WB, Sposto R, Friedman D, Tebbi CK, Mendenhall NP, Villaluna D, De Alarcon PA, Chauvenet A. In reply [2] Journal of Clinical Oncology. 20 July 2007;25(21):3180.

139. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev. 2002 Jan;16(1):34-45.

140. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999 Mar 11;340(10):764-71.

141. Korones DN, Weidner S, Schwartz CL. Intermittent high-dose deferoxamine for patients with iron overload and sickle cell anemia International Journal of Pediatric Hematology/Oncology. 1996;3(1):53-56.

142. Rohr LR, Koss LG, Nitschke R, Schwartz CL, Miller NR, Wharam MD, Leventhal BG. Letter to the editor Cancer. 15 March 1990;65(6):1460-1462.

143. Schwartz CL, Miller NR, Wharam MD, Leventhal BG. To the editor (I: Reply) Cancer. 1990;65(6):1462.

144. Weisman AJ, Kim J, Lee I, McCarten KM, Kessel S, Schwartz CL, Kelly KM, Jeraj R, Cho SY, Bradshaw TJ. Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients. EJNMMI Phys. 2020 Dec 14;7(1):76. PMCID: PMC7736382

145. Giulino-Roth L, Pei Q, Buxton A, Bush R, Wu Y, Wolden SL, Constine LS, Kelly KM, Schwartz CL, Friedman DL. Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group. Blood. 2021 Mar 18;137(11):1449-1456. PMCID: PMC7976513

146. Lo AC, Dieckmann K, Pelz T, Gallop-Evans E, Engenhart-Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28562.

147. Milgrom SA, Kim J, Chirindel A, Kim J, Pei Q, Chen L, Buxton A, Kessel S, Leal J, McCarten KM, Hoppe BS, Wolden SL, Schwartz CL, Friedman DL, Kelly KM, Cho SY. Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031. Pediatr Blood Cancer. 2021 Sep;68(9):e29212. PMCID: PMC8809108

148. Chow EJ, Aplenc R, Vrooman LM, Doody DR, Huang YV, Aggarwal S, Armenian SH, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Asselin BL, Schwartz CL, Lipshultz SE. Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group. Cancer. 2022 Feb 15;128(4):788-796. PMCID: PMC8792306

149. Johnston RL, Mottok A, Chan FC, Jiang A, Diepstra A, Visser L, Telenius A, Gascoyne RD, Friedman DL, Schwartz CL, Kelly KM, Scott DW, Horton TM, Steidl C. A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. Blood. 2022 Feb 10;139(6):889-893. PMCID: PMC8832480

150. Lipshultz ER, Chow EJ, Doody DR, Armenian SH, Asselin BL, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Schwartz CL, Lipshultz SE, Vrooman LM. Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group. Cancer Epidemiol Biomarkers Prev. 2022 Mar 01;31(3):536-542. PMCID: PMC9067064

151. Milgrom SA, Kim J, Hoppe BS, Pei Q, Wu Y, Lo AC, Kessel S, McCarten KM, Roberts KB, Hodgson D, Schwartz C, Friedman D, Kelly KM, Cho SY. PET-Based Quantification of Baseline Metabolic Tumor Burden Improves Risk Stratification in High-Risk Hodgkin Lymphoma: A Children's Oncology Group Study International journal of radiation oncology, biology, physics. 1 November 2021;111(3):S79-S80.

152. Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):890-900. PMCID: PMC9038118

153. Kahn JM, Pei Q, Friedman DL, Kaplan J, Keller FG, Hodgson D, Wu Y, Appel BE, Bhatia S, Henderson TO, Schwartz CL, Kelly KM, Castellino SM. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials. Lancet Haematol. 2022 Jan;9(1):e49-e57. PMCID: PMC8815096

154. Parekh A, Keller FG, McCarten KM, Kessel S, Cho S, Pei Q, Wu Y, Castellino SM, Constine LS, Schwartz CL, Hodgson D, Kelly KM, Hoppe BS. Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis. Blood. 2022 Sep 08;140(10):1086-1093. PMCID: PMC9461469

155. Werk RS, Koyama T, Sun L, Wolden S, Kelly KM, Constine LS, Schwartz CL, Friedman DL. Post-Traumatic Stress Symptoms in Adolescent Hodgkin Lymphoma Survivors: A Report from Children's Oncology Group AHOD0031. J Adolesc Young Adult Oncol. 2023 Jun;12(3):359-365. PMCID: PMC10282797

156. Valencia MC, Hang L, Schmidt D, Nichols J, Zhang J, Yan K, Gonzalez A, Schwartz CL, Phelan R. Next Steps: Survivor Healthcare Passport - A Novel Form of Survivorship Care Plan in the Pediatric Population. J Pediatr Hematol Oncol. 2023 Jul 01;45(5):e573-e577.

157. Chow EJ, Aggarwal S, Doody DR, Aplenc R, Armenian SH, Baker KS, Bhatia S, Blythe N, Colan SD, Constine LS, Freyer DR, Kopp LM, Laverdière C, Leisenring WM, Sasaki N, Vrooman LM, Asselin BL, Schwartz CL, Lipshultz SE. Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer. J Clin Oncol. 2023 Apr 20;41(12):2248-2257. PMCID: PMC10448941

158. Phadnis S, Wang X, Daw NC, Herzog CE, Subbiah IM, Zaky W, Gouda MA, Morani AC, Amini B, Harrison DJ, Piha-Paul SA, Meric-Bernstam F, Gorlick R, Schwartz CL, Subbiah V. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study. ESMO Open. 2023 Dec;8(6):101609. PMCID: PMC10774869

159. Lo AC, Liu A, Liu Q, Yasui Y, Castellino SM, Kelly KM, Hererra AF, Friedberg JW, Friedman DL, Schwartz CL, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine LS, Hodgson DC. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Netw Open. 2024 Jan 02;7(1):e2351062. PMCID: PMC10799264

1. Schwartz CL, Cohen HJ. Myeloproliferative and myelodysplastic syndromes. In: Principles and Practice of Pediatric Oncology. Ed(s) Pizzo PA, Poplack DG. JB Lippincott Company: Philadelphia, PA, 397-413, 1989.

2. Schwartz CL. Myelodysplastic and myeloproliferative disorders in children. In: Hematology: Basic Principles and Practice. Ed(s) Hoffman R, Benz EJ, Shattil S, Furie B, Cohen HJ. Churchill Livingstone: New York, 889-896, 1991.

3. Schwartz CL. Cancers in Childhood. In: Pediatric Primary Care. Ed(s) Hoekelman R. Mosby: St. Louis, MO, 1157-1179, 1992.

4. Schwartz, CL. Retinoblastoma. In: Merck Manual, 16th Edition. Ed(s) Berkow R. Merck, Sharp & Dohme Research Laboratories: Rahway, New Jersey, 2205-2206, 1992.

5. Schwartz CL, Cohen HJ. Myeloproliferative and myelodysplastic syndromes. In: Principles and Practice of Pediatric Oncology, 2n edition. Ed(s) Pizzo PA, Poplack DG. JB Lippincott Company: Philadelphia, PA, 519-535, 1993.

6. Schwartz CL, Constine LC, Putnam TC, Cohen HJ. Pediatric solid tumors. In: Clinical Oncology, A Multidisciplinary Approach, 7th edition. Ed(s) Saunders WB, 251-298, 1993.

7. Schwartz CL, Truesdell SA, Clark EB. The Use of the QTc in screening for anthracycline related cardiotoxicity. In: Cardiac toxicity cardiomyopathy after Cancer Therapy. Ed(s) Bricker GT, D'Angio GJ, Green DM. John Wiley and Sons: New York, 103-108, 1993.

8. Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Algorithms of Late Effects by Disease. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook: Missouri, 7-20, 1994.

9. Truesdell S, Schwartz CL, Clark E. Cardiovascular Effects of Therapy. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook, Inc.: Missouri, 159-176, 1994.

10. Constine LS, Hobbie WL, Schwartz CL. Facilitated Assessment of Chronic Treatment Effects by Symptom and Organ Systems. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook, Inc.: Missouri, 21-80, 1994.

11. Constine LS, Hobbie WL, Schwartz CL. Facilitated Assessment of Chronic Treatment Effects by Symptom and Organ Systems. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook, Inc.: Missouri, 7-20, 1994.

12. McDonald S, Rubin P, Schwartz CL. Pulmonary Effects of Antineoplastic Therapy. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook, Inc.: Missouri, 177-196, 1994.

13. Schwartz CL, Hobbie WL, Ruccione K, Constine LS. The Establishment of the follow-up Clinic. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Ruccione K, Constine LS. Mosby Yearbook, Inc.: Missouri, 367-389, 1994.

14. Constine LS, Schwartz CL. The Thyroid Gland. In: Survivors of Childhood Cancer - Assessment and Management. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Mosby Yearbook, Inc: Missouri, 151-158, 1994.

15. Schwartz, CL. Myelodysplastic and myeloproliferative disorders in children. In: Hematology: Basic Principles and Practice, 2nd edition. Ed(s) Benz EJ, Cohen HJ, Furie B, Hoffman R, Sharril S. Churchill Livingstone: New York, 1184-1192, 1995.

16. Schwartz CL. Cancers in Childhood. In: Pediatric Primary Care, 3rd Edition. Ed(s) Hoekelman R. Mosby Yearbook, Inc: Missouri, 1217-1238, 1997.

17. Korones DN, Schwartz CL. Myeloproliferative and myelodysplastic syndromes. In: Principles and Practice of Pediatric Oncology, 3rd Edition. Ed(s) Oldham KT, Colombani PM, Foglia RP. Lippincott-Raven: Philadelphia, 537-48, 1997.

18. Schwartz CL, Cohen HJ. Myeloproliferative and myelodysplastic syndromes. In: Principles and Practice of Pediatric Oncology, 3rd Edition. Ed(s) PA Pizzo, Poplack DG. JB Lippincott Company: Philadelphia, 505-521, 1997.

19. Korones DN, Schwartz CL. Principles of Oncology. In: Surgery of Infants and Children. Ed(s) Oldham KT, Colombani PM, Foglia RP. Lippincott-Raven: Philadelphia, 537-48, 1997.

20. Chauvenet, A, Schwartz CL, Weiner M. Hodgkin’s Disease in Children and Adolescents. In: Cancer Medicine, 5th Edition. Ed(s) Holland, Frei. B.C. Decker Inc, 2140-2150, 2000.

21. Schwartz, CL. Myelodysplastic and myeloproliferative disorders in children. In: Hematology: Basic Principles and Practice. Ed(s) Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P. Churchill Livingstone: New York, 1205-1212, 2000.

22. Constine LC, Paidas C, Schwartz CL, Korones DN. Pediatric solid tumors. In: Clinical Oncology, A Multidisciplinary Approach, 8th Edition. Ed(s) Rubin P. WB Saunders, 336-404, 2001.

23. Ruble K, Schwartz C. Sports for the Child with Cancer. In: ” Educating the Child with Cancer: A Guide for Parents & Teachers, Nancy Keen. Candlelighters Childhood Cancer Foundation, 2003.

24. Loeb D, Castleberry R, Schwartz CL. Myelodysplastic and myeloproliferative disorders in children. In: Hematology: Basic Principles and Practice. Ed(s) Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McFlave P. Churchill Livingstone: New York, 1297-1306, 2004.

25. Simpson L, Baird K, Korones DN, Schwartz CL. Principles of Oncology. In: Surgery of Infants and Children. Ed(s) Foglia RP. Lippincott-Raven: Philadelphia, 2004.

26. Schwartz CL, Hobbie, WL, Constine, L. Algorithms of Late Effects by Disease. In: Survivors of Childhood and Adolescent Cancer – A Multidisciplinary Approach. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Springer-Verlag & Co, 5-16, 2005.

27. Schwartz CL, Hobbie, WL, Constine, L. Facilitating Assessment of Late Effects by Organ System. In: Survivors of Childhood and Adolescent Cancer – A Multidisciplinary Approach. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Springer-Verlag & Co, 17-34, 2005.

28. Biswas T, Constine LS, Schwartz CL. The Thyroid Gland. In: Survivors of Childhood and Adolescent Cancer – A Multidisciplinary Approach. Ed(s) Schwartz CL, Hobbie WL, Constine LC, Ruccione KS. Springer-Verlag & Co: Heidelberg, Germany, 125-132, 2005.

29. Hudson MM, Schwartz C, Constine LS. Treatment of Pediatric Hodgkin Lymphoma. In: Pediatric Lymphomas. Ed(s) Weinstein HJ, Hudson MM, Link MP. Springer: Heudekberg, Germany, 35-66, 2007.

30. Hinkle AS, Schwartz CL. Cancers in Childhood. In: Textbook of Pediatric Care. Ed(s) McInerny TK. American Academy of Pediatrics: Elk Grove Village, IL, 1873-1902, 2009

31. Schwartz CL. Early Response-based Therapy for Children with Hodgkin Lymphoma: A Surrogate for Using Biology to Effect Cure and Minimize Toxicity. In: ASCO Educational Book, 2010.

32. Ruble K, Schwartz C. Physical Activity. In: Educating the Child with Cancer: A Guide for Parents & Teachers. Ed(s) Keen N. American Childhood Cancer Organization, 2011.

33. Greene Welch J, Schwartz C, “Hodgkin Lymphoma” in Clinical Decision Support: Pediatrics edited by McMillian JM, Barrett DJ, Boney CM, Jones MD (2012). Decision Support in Medicine LLC Wilmington, DE

34. Schwartz CL. Hodgkin Lymphoma (Commentary). In: Evidence Based Pediatric Oncology, 3rd Edition. Ed(s) Pinkerton R, Shankar A, Matthay KK. Wiley-Blackwell, 105-108, 2013.

35. Greene Welch J, Schwartz C, “Hodgkin Lymphoma” in Clinical Decision Support: Pediatrics edited by McMillian JM, Barrett DJ, Boney CM, Jones MD (2016). Decision Support in Medicine LLC Wilmington, DE.

36. Greene Welch J, Hackney L, Schwartz CL, “Cancers in Childhood” in American Academy of Pediatrics Textbook of Pediatric Care, 2015.

1. Schwartz CL. Health status of childhood cancer survivors: cure is more than the eradication of cancer. JAMA. 2003 Sep 24;290(12):1641-3.

2. Schwartz CL. Health status of adult long-term survivors of childhood cancer:a report from the Childhood Cancer Survivor Study. J Pediatr. 2004 Mar;144(3):407-8.

3. Schwartz, CL. Curing Hodgkin Disease: Too much of a good thing. Current Controversies in Oncology, ASCO News and Forum:21-22, 4/2007.

4. 4. Schwartz, CL. “Creating a bridge for transition: From pediatric cancer survival to life-long risk-based health care of the adult cancer survivor". Cancer Feb 1;126(3):473-476, 2020. PMID: 31626326

1. Schwartz CL, Constine LC, Putnam TC, Cohen HJ. Pediatric solid tumors. In: Clinical Oncology, A Multidisciplinary Approach, 7th edition. Ed(s) Saunders WB, 251-298, 1993.

2. Schwartz CL, Truesdell SA, Clark EB. The Use of the QTc in screening for anthracycline related cardiotoxicity. In: Cardiac toxicity cardiomyopathy after Cancer Therapy. Ed(s) Bricker GT, D'Angio GJ, Green DM. John Wiley and Sons: New York, 103-108, 1993.

3. Schwartz CL, Friedman DL, McCarten K, Wolden S L, Voss S, Constine LS. Chen L. Early PET and CT as predictors of outcome in pediatric Hodgkin lymphoma, Society International Pediatric Oncology. Pediatric Blood Cancer 57(5):75, 2011.

4. Castellino C, keller F, Dunphy C, Nachman J, Constine L, Chen L, Schwartz C. Mixed Cellularity Histology Confers Favorable Prognosis in Children and Adolescents with Low Risk Hodgkin Lymphoma (HL). 1st International Symposium on Childhood, Asolescent, and Young Adulty Hodgkin Lymphona, 2011

5. Schwartz CL, Friedman DL, McCarten K, Wolden SL, Voss S, Constine LS, Chen L. Predictors of Early Response and Event Free Survival in Hodgkin Lymphoma (HL): PET vs CT Imaging. Proceedings ASCO, 2011

6. Fernandez KS, Chen L, Schwartz C, Chauvenet A, deAlarcon PA. Survival in Adolescents and Young Adults with Hodgkin Lymphoma Treated with Response-Based Chemotherapy on P9425 and P9426 Protocols: A Report From the Children’s Oncology Group. Blood 118:91, 2011.

7. Schwartz C, Chen L, Constine L, Wolden S, Keller FG, Kelly KM, Friedman DL. The Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event Free Survival in Pediatric and Adolescent Hodgkin Lymphoma. Blood 118:3649, 2011.

8. Appel B, Chen L, Hutchison RE, Hodgson DC, Ehrlich P, Constine LC, Schwartz CL. 18F-FDG (FDG) OET Five-Point Visual and Quantitative SUV-Based Assessment and Prognosis in Pediatric Hodgkin Lymphoma (HL). ASH, 2012.

9. Schwartz CL, Kaplan J, Chen L, Hutchison R, Friedman D. Albumin: A Predictor of EFS in MC Hodgkin Lymphoma. SIOP, 2012

10. Gorlick R, Barkauskas D, Krailo M, Piperdi S, Sowers R, Gorlick S, Gill J, Geller D, Randall L, Janeway K, Schwartz C, Grier H, Meyers P, Bernstein M, Marina N. HER2 Expression is Not Prognostic in Osteosarcoma. CTOS, 2012.

11. Kopp L, Bernstein ML, Schwartz CL, Ebb D, Krailo MD, Frier HE, Meyers PA,k Wexler LH, Marina N, Womer R, Janeway KA, Gorlick RG, Lipshultz SE. The Effects of Dexrazoxane on Cardiac Funtion and Secondary Malignant Neoplasms in Patients with Osteosarcoma (OS). Proceedings ASCO, 2012.

12. Appel B, Ehrlich P, Chen L, Hutchison RE, Hodgson DC, Constine LS, Schwartz CL. Treatment of Pediatric Stage IA Lympocyte-Predominant Hodgkin Lympoma with Surgical Resection Alone: A COG Report. Proceedings ASCO, 2012

13. Schwartz CL, Hirway P, Ader J, Bradeen HA, Grewal SS, Huang MS, Kadan-Lottick N, Usmani N, Kenney LB. Barriers to Survivorship Care - CONNECCS. Proceedings ASCO, 2013.

14. Appel B, Chen L, Hutchison RE, Hodgson DC, Ehrlich P, Constine LC, Schwartz CL. Treatment of pediatric lymphocyte predominant Hodgkin lymphoma (LPHL): A report from the Children's Oncology Group,. Proceedings ASCO, 2013.

15. Welch J, Bjerregaard J, Jelalian E, Spoerri M, Schwartz C. YMCA Healthy Living Educational Pilot Program for Children and Adolescent Survivors of Cancer. American Psychosocial Oncology Society, Tampa, FL, February 2014.

16. Keller F, Castellino S, Constine L, Voss S, Thomson J, Dunphy C, McCarten K, Chen L, Schwartz CL. Intensive Therapy Free Survival (ITFS) for Early-Stage Hodgkin Lymphoma (cHL) Including Chemotherapy and Radiation Therapy (IFRT) for Recurrence after Chemotherapy Alone. Klinische Padiatrie 226(02), 2014. DOI: 10.1055/s-0034-1371119

17. Charpentier A, Friedman D, Wolden S, Schwartz C, Gill B, Sykes J, Albert-Green A, constine L, Kelly K, Hodgson D. Predictive Factor Analysis of Response-adapted Treatment for Chemotherapy-sensitive Pediatric Hodgkin Lymphoma: a Report from Children's Oncology Group Trial AHOD003. , 2014.

18. Rao P, Hirway P, Welch JG, Schwartz CL. “Perspectives Regarding Fertility in Female Adolescent and Young Adult Childhood Cancer Survivors.” Poster presentation, American Society of Hematology, San Francisco, CA, December 2014

19. SM Castellino, F Keller, SVoss, S Cho, L Constine, JT homson, C Dunphy, K McCarten L Chen, and CLSchwartz. Outcomes and Patterns of Failure in Children/Adolescents with Low Risk Hodgkin Lymphoma (HL) Who are FDG-PET (PET3) Positive After AVPC Therapy. ISCAYAHL, 5/2015.

20. Subbiah V, Anderson P, W. Huh, Hess K, Ravi V, FernandezJG, Lui A, Daw N, Somaiah N, Kappadath C, Ravissini G, Ludwig J, ChawlaS, Benjamin RS, Patel S, Schwartz CL, Hong DS, Rohren E. Safety, Tolerability, and Feasibility of Alpha Particle Radium-223 Dichloride (223RaCI2) in High Risk Osteosarcoma: Phase I Dose Escalation Trial. Connective Tissue Oncology Society, 10/2015.

21. Moonat HR, Wang WL, Kenneth R. Hess, Schwartz CL, Moise M, Patel S, Benjamin RS, Lewis VO, Lazar A, Daw NC. Small Cell Osteosarcoma: The MD Anderson Cancer Center Experience. Connective Tissue Oncology Society, 10/2015.

22. Spaker-Perlman HL, Barkauskas DA, Meyers PA; Schwartz CL, Ebb DH, Doski JJ, Krailo MD, Gorlick R, Janeway KA. Survivial After Recurrence in Osteosarcoma: A Report from the Chidlren's Oncology Group. Connective Tissue Oncology Society, 10/2015.

23. Appel B, Chen L, Hutchison RE, Hodgson DC, Ehrlich P, Constine LC, Schwartz CL. 18F-FDG (FDG) PET Five-Point Visual and Quantitative SUV-Based Assessment and Prognosis in Pediatric Hodgkin Lymphoma (HL), A Preliminary Retrospective Analysis of Children’s Oncology Group (COG) AHOD0031. Blood (ASH poster) Supplement, 2015.

24. Henderson TO, Parson SK, Wroblewski K, Chen L, Hong F, Smith SM, McNeer J, Advani R, Gascoyne RD, Constine L, Horning SJ, Bartlett NL, MD, Shah BD, MD, Connors JM, Leonard JP, Kahl BS, Kelly KM, Schwartz CL, Friedman DL,Gordon Li, Evens AM. Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treat on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031). Blood (ASH poster) Supplement, 2015.

25. Kelly KM, MD, Cole PD, Chen L, Robrets KB, Hodgson DC, McCarten K, Steve Y Cho SY, Schwartz C. Phase III Study of Response Adapted Therapy for the Treatment of children with Newly Diagnosed Very HIgh Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group. Blood, 2015.

26. Mottok A, Johnston RL, Chan FC, Scott DW, Friedman DL, Schwartz CL, Kelly K, Terzah M. Horton TM.Steidl C. Prediction of Primary Treatment Outcome Using Gene Expression Profiling of Pre-Treatment Biopsies Obtained from CHhildhood and Adolescent Hodgkin Lympjoma Patients. Blood Supplement(126), 12/2015

27. Shaw A, Schadler K, Schwartz CL, Kleinerman E. Exercise Preconditioning Mitigates Doxorubicin Uptake in Cardiac Tissue. Pediatric Blood and Cancer 63(S1):S66 (#4010), 5/2016.

28. Lewis B, Kresta K, Shaw A, Robert R, Maetzold B, Valderrama R, Harman N, Cion I, Franklin Q Morse E, Skillman D, Schwartz CL, Tewari P. Totally Excited about Moving, Mobility and Exercise: a Multidisciplinary Effort to Help Increase Mobility for Children, Adolescents and Young Adults During their Inpatient Admission. Pediatric Blood and Cancer 63(S1):S9, 5/2016.

29. Chow EF, Doody DR, Armenian SH, Aggarwal S, Baker KS, Bhatia S, Blythe NA, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Sasake N, Vrooman LM, Asselin BL, Schwartz CL, Lipshultz SE. Effect of Dexrazoxane on Heart Function Among LongTerm Leukemia and Lymphoma: A Report from the Children's Oncology Group (COG). ASH oral presentation 2016. In Press.

30. Giulino-Roth L, Pei Q, Buxton A, Wolden S, Constine LS, Kelly K, Schwartz CL, Friedman DL. Subsequent Malignant Neoplasms Among Children and Adolescents with Hodgkin Lymphoma Treated with Response-Adapted Therapy: A Report From The Children's Oncology Group Study AHOD0031. ASH poster 2016. In Press.

31. Moonat HR, Roxas M, Huh WW, Herzog CE, Piha-Paul S, Daw NC, Rytting M, Mote E, Ward EN, Amin Y, Meric-Bernstam F, Schwartz CL, Subbiah V. Phase I evaluation of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in children, adolescents and young adults with advanced solid tumors. Cancer Research 76(5 Supplement) (#A48), 3/2016.

32. Mottok A, Johnston RL, Chan FC, Scott DW, Friedman DL, Schwartz CL, Kelly KM, Horton TM.Steidl C. Prediction of primary treatment response and outcome using digital gene expression. 10th International Symposium of Hodgkin Lymphoma, Cologne, Germany. October 2016.

33. Kelly KM, Cole PD, Chen L, Roberts KB, Hodgson DC, McCarten K, Cho S, Schwartz CL. Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group. 10th International Symposium of Hodgkin Lymphoma, Cologne, Germany. October 2016.

34. Schwartz CL, Wolden S, Constine LC, Chen L, Friedman DL. CHIPS as a predictor of outcome in radiated vs. unradiated HL. 10th International Symposium of Hodgkin Lymphoma, Cologne, Germany. October 2016.

35. Kopp LM, Bernstein ML, Schwartz CL, et. al. Complete Dexrazoxane Cardioprotection for Cardiac Function but Incomplete Female Cardioprotection for Cardiac Structure in Doxorubicin-treated Osteosarcoma Survivors: Hearts Too Small for The Body. ASCO, submitted 2017.

36. Phadnis S, Huh, WW, Hezog CE, Daw NC, Harrision D, Ward EN, Piha-Paul S, Bhatt T, Mote E, Gorlick R, Meric-Bernstam F, Schwartz CL, Subbiah V. Phase I study of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in children, adolescents and young adults with sarcoma and other advanced solid tumors. Connective Tissue Oncology Society, Maui, HI. 2017.

37. Lipshultz ER, Chow EJ, Kopp LM, Doody DR, Armenian SH, Asselin BL, Baker KS, Bhatia S, Constine LS, Freyer DR, Laverdiere C, Schwartz CL, Lipshultz SE, Vrooman LM. Cardiometabilic risk in childhood cancer survivors: a Children’s Oncology Group study. ASCO, Chicago, IL. 2018

38. Schwartz CL, Oldham R, Faber ML, Lum LG, Medin JA. Development of an α-CD30 Bispecific Antibody Immunotherapy for Hodgkin Lymphoma. 11th International Symposium on Hodgkin Lymphoma. Cologne, 2018

39. Becktell K, Schwartz CL. Investigating the Need for a Multidisciplinary Cancer Predisposition Clinic. American Society of Pediatric Hematology, 2018.

40. Becktell K, Schwartz CL. Investigating the Need for a Multidisciplinary Cancer Predisposition Clinic. Pediatric Academic Society, 2018.

41. Kahn JM, Kelly KM, Pei Q, Friedman DL, Keller FG, Bush R, Bhatia S, Hernderson TO, Schwartz CL, Castellino SM. Survival by age in children and adolescents with Hodgkin lymphoma: A pooled analysis of Children’s Oncology Group (COG) trials. ASCO, Chicago, IL. 2018.

42. Evens A, Ranjana A, Aleman B…Schwartz CL…Parsons S. The Hodgkin Lymphoma Internationa Study for Individual Care (HOLISTIC): enhancing decision making in pediatric and adult Hodkgin Lymphoma (HL), European Hematology Association. 2020.

43. Kahn JM, Kelly KM, Pei Q, Friedman DL, Keller FG, Bush R, Bhatia S, Hernderson TO, Schwartz CL, Castellino SM. The Impact of age on outcomes in classical Hodgkin lymphoma (HL) varies by histology: A Report from the Children’s Oncology Group (COG), submitted ASH, 2020

44. Bergeron GravelS, Khandwala M, Wolden SL, Castellino SM, Friedman /DL, Kelly KM, Roberts KB, Constine LS, Schwartz CL, Fitzgerald TJ, Hoppe BS, Hodgson D. Reduction in Cardiac Radiation Dose Among Children Receiving Mediatstinal RT: Comparison of Involved-Site vs Involved-Field RT delivered in Three Children’s Oncology Group trials. ISCAYAHL Klinische Pädiatrie 2020; 232: 102, 2020

45. Giulino-Roth L, Pei Q, Buxton A, Bush R, Wolden SL, Constine LS, Kelly KM, Schwartz CL, Friedman DL. Subsequent Malignant Neoplasms Among Children and Adolescents with Hodgkin Lymphoma Treated with Response-Adapted Therapy: A Report from the Children’s Oncology Group Study AHOD0031. ISCAYAHL Klinische Pädiatrie 2020; 232: 104, 2020.

46. Kahn JM, Kelly KM, Pei Q, Friedman DL, Keller FG, Bhatia S, Henderson TO, Schwartz CL , Castellino SM. Outcomes by age in pediatric and adolescent patients treated for de novo Hodgkin lymphoma on contemporary Children’s Oncology Group trials. ISCAYAHL Klinische Pädiatrie 2020; 232: 104, 2020.

47. Chow EF, Aggarwal S, Doody DR, …Schwartz CL, Lipshultz SE. Dexrazoxane and Heart Function among Long-Term Childhood Cancer Survivors: a Children’s Oncology Group study. Submitted ASCO 2020.

48. Hang L, Schmidt D, Nichols J, Zhang J, Yan K, Schwartz CL, Phelan R. Next Steps: Survivor Healthcare Passport, a Nnovel form of Survivorhip Care Plans in the Pediatraic Population.

49. Parikh RR, Hoppe BS, Hodgson D, McCarten KM, Pei Q, Cho SY, Schwartz C, Cole P, Kelly KM, Roberts KB. Patterns of Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group. Submitted ASTRO, 2020

50. Chao K, Stoddart A, Schwartz CL, Becktell K. Familial Wilms tumor secondary to germline REST mutation, American Society of Pediatric Hematology Oncology, submitted 2020.